KGKatarina Sjögreen Gleisner

Katarina Sjögreen Gleisner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katarina Sjögreen Gleisner has a total of 164 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dimensionality reduction for partial-volume correction in quantitative SPECT

    by Johan Gustafsson, Erik Larsson, Katarina Sjögreen Gleisner

    Objective . The aim of this paper is to develop a method for region-based post-reconstruction partial-volume correction (PVC) of single photon emission computed tomography (SPECT) images, which explicitly estimates the mean activity concentration in regions without assuming strict intra-regional uniformity. Approach . PVC was applied to 177 Lu-SPECT images obtained from the simulation of eight anthropomorphic phantoms as well as two example patients. Both sets of data were reconstructed using OS-EM with ten subsets and up to 40 iterations, including compensation for attenuation, scatter, and spatial resolution. Reconstructed images were deconvolved using the van Cittert algorithm and Lucy–Richardson algorithm, both implemented on images represented as standard cuboid voxels or as regional voxels, consisting of regions defined from whole-image segmentation. Methods embedding regional voxels were applied both assuming region-wise uniform activity concentration and incorporating perturbations in the form of cosine series to relax the uniformity assumption. For comparison, images were also processed with the iterative Yang method and MIRD recovery coefficients. Evaluation was performed with respect to the estimated activity concentration for kidneys, spleen, and tumours, as well as the total activity in the images. Main results . Mean activity-concentration errors prior to PVC were (−22.6 ± 11.5) %, (−13.8 ± 2.1) %, and (−7.4 ± 2.8) % for tumours, kidneys, and spleen, respectively. Region-perturbed van Cittert deconvolution with order 4 reduced these errors to (2.3 ± 7.7) %, (0.3 ± 2.2) %, and (4.0 ± 1.6) % while the errors for region-perturbed Lucy-Richardson deconvolution of order 4 were (0.3 ± 8.0) %, (0.0 ± 1.6) %, (2.6 ± 0.5) %. Corresponding results for the iterative Yang method were (2.8 ± 21) %, (−0.3 ± 2.1) %, and (3.8 ± 2.4) % and using MIRD recovery coefficients (−5.0 ± 14.2) %, (−7.1 ± 1.9) %, and (−0.6 ± 3.1) %. Significance . Region-based PVC improves the accuracy of quantitative SPECT, and the inclusion of cosine perturbations allows for a gradual relaxation of the uniformity assumption.

  • Open Access

    Improved patient models for simulation of clinically realistic 68Ga-SSTR PET and 177Lu-PRRT SPECT studies

    by Johan Gustafsson, Philip Kalaitzidis, Selma Curkic Kapidzic, Michael Ljungberg, Katarina Sjögreen Gleisner

    Background: The aim was to improve the realism of patient models for Monte-Carlo based evaluation of image-based quantification of tumour volume and activity in [ 68 Ga]Ga-DOTA-TOC PET and [ 177 Lu]Lu-DOTA-TATE SPECT images. Methods: Three phantoms from the XCAT population were used as basis. Tumour structures were obtained from segmentation of patient 68 Ga-PET images and positioned at relevant positions in the phantoms. Respiratory motion was modelled, and the centre-of-mass of tumours displaced according to the organ motion in the respiration. Tumour activity concentrations were sampled from a log-normal distribution derived from patient data. Intra-organ non-uniform activity concentration was modelled for spleen, liver, and intestines. The full phantom models included all these aspects. For assessment of the impact of the modelled effects, simulations were also carried out for phantoms without respiratory motion (full-without-motion) and with spherical lesions without background variability (standard models). Evaluation was focussed on the impact of the models on the errors in tumour activity concentrations estimated from SPECT and PET images with and without partial-volume correction (PVC). Results: The full models were successfully realized and were found to yield a visual appearance that more closely resembled that of patients, compared to the full-without-motion and standard models. For tumours in the volume range 0 mL to 10 mL, the mean relative errors obtained for 177 Lu-SPECT without PVC were − 51%, -38%, and − 34% for the full models, the full-without-motion models, and the standard models, respectively. Corresponding results for 68 Ga-PET without PVC were − 34%, -25%, and − 23%. Thus, for both PET and SPECT, the negative bias in estimated tumour activity concentrations demonstrated a clear sensitivity to the taken modelling approach. Conclusions: Respiratory motion is an important factor for modelling realistic patient images, in the context of quantitative SPECT and PET. Non-spherical tumours and background variability has a minor, but measurable impact.

  • Open Access

    Clinical Trials in Molecular Radiotherapy: An Overview of the Landscape

    by N. Varmenot, K. Sjögreen Gleisner, J. Taprogge, G.D. Flux

  • Open Access

    EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy

    by Katarina Sjögreen-Gleisner, Glenn Flux, Klaus Bacher, Carlo Chiesa, Robin de Nijs, George C. Kagadis, Thiago Lima, Maria Lyra Georgosopoulou, Pablo Minguez Gabiña, Stephan Nekolla, et al.


  • Top Cited Papers
    Open Access

    EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

    by Katarina Sjögreen Gleisner, Nicolas Chouin, Pablo Minguez Gabina, Francesco Cicone, Silvano Gnesin, Caroline Stokke, Mark Konijnenberg, Marta Cremonesi, Frederik A. Verburg, Peter Bernhardt, et al.

    The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.


  • Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with177Lu-DOTATATE

    by Daniel Roth, Johan Gustafsson, Carl Fredrik Warfvinge, Anna Sundlöv, Anna Åkesson, Jan Tennvall, Katarina Sjögreen Gleisner

    Tumor dosimetry was performed for 177Lu-DOTATATE with the aims of better understanding the range and variation of the tumor-absorbed doses (ADs), how different dosimetric quantities evolve over the treatment cycles, and whether this evolution differs depending on the tumor grade. Such information is important for radiobiologic interpretation and may inform the design of alternative administration schemes. Methods: The data came from 41 patients with neuroendocrine tumors (NETs) of grade 1 (n = 23) or 2 (n = 18) who had received between 2 and 9 treatment cycles. Dosimetry was performed for 182 individual lesions, giving a total of 880 individual AD assessments across all cycles. Hybrid planar–SPECT/CT imaging was used, including quantitative SPECT reconstruction, voxel-based absorbed-dose-rate calculation, semiautomatic image segmentation, and partial-volume correction. Linear mixed-effect models were used to analyze changes in tumor ADs over cycles, absorbed-dose rates and activity concentrations on day 1, effective half-times, and tumor volumes. Tumors smaller than 8 cm3 were excluded from analyses. Results: Tumor ADs ranged between 2 and 77 Gy per cycle. On average, the AD decreased over the cycles, with significantly different rates (P < 0.05) of 6% and 14% per cycle for grade 1 and 2 NETs, respectively. The absorbed-dose rates and activity concentrations on day 1 decreased by similar amounts. The effective half-times were less variable but shorter for grade 2 than for grade 1 (P < 0.001). For grade 2 NETs, the tumor volumes decreased, with a similar tendency in grade 1. Conclusion: The tumor AD, absorbed-dose rate, and activity uptake decrease, in parallel with tumor volumes, between 177Lu-DOTATATE treatment cycles, particularly for grade 2 NETs. The effective half-times vary less but are lower for grade 2 than grade 1 NETs. These results may indicate the development of radiation-induced fibrosis and could have implications for the design of future treatment and dosimetry protocols. Visual Abstract


  • Open Access

    3-D Image-Based Dosimetry in Radionuclide Therapy

    by M. Ljungberg, K. Sjogreen Gleisner

    Radionuclide therapy is the use of radioactive drugs for internal radiotherapy, mainly for the treatment of metastatic disease. As opposed to systemic cancer therapies in general, the use of radioactively labeled drugs results not only in a targeted therapy but also the possibility of imaging the distribution of the drug during therapy. From such images, the absorbed doses delivered to tumors and organs at risk can be calculated. Calculation of the absorbed dose from 3-D images such as single-photon emission computed tomography (SPECT)/CT, and in some cases positron emission tomography (PET)/CT, relies on image-based activity quantification. Quantification is accomplished by modeling the physics involved in the image-formation process, and applying image-processing methods. From a time-sequence of such quantitative images, the absorbed doses are then calculated. Although individual-patient dosimetry is a standard component of other forms of radiotherapy, it is still overlooked in the majority of radionuclide therapies. In this review, we summarize the physical and technical problems that need to be addressed in image-based dosimetry. The focus is on SPECT, since most of the radionuclides used are single-photon emitters, although the use of PET is also discussed. Practical issues of relevance for the practical implementation of personalized dosimetry in radionuclide therapy are also highlighted.


  • Open Access

    Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey

    by Katarina Sjögreen Gleisner, Emiliano Spezi, Pavel Solny, Pablo Minguez Gabina, Francesco Cicone, Caroline Stokke, Carlo Chiesa, Maria Paphiti, Boudewijn Brans, Mattias Sandström, et al.

    Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability of dosimetry-based MRT in clinical practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries. An electronic questionnaire was distributed to European countries. This addressed 18 explicitly considered therapies, and for each therapy, a similar set of questions were included. Questions covered the number of patients and treatments during 2015, involvement of medical specialties and medical physicists, implementation of absorbed dose planning, post-therapy imaging and dosimetry, and the basis of therapy prescription. Responses were obtained from 26 countries and 208 hospitals, administering in total 42,853 treatments. The most common therapies were 131I-NaI for benign thyroid diseases and thyroid ablation of adults. The involvement of a medical physicist (mean over all 18 therapies) was reported to be either minority or never by 32% of the responders. The percentage of responders that reported that dosimetry was included on an always/majority basis differed between the therapies and showed a median value of 36%. The highest percentages were obtained for 177Lu-PSMA therapy (100%), 90Y microspheres of glass (84%) and resin (82%), 131I-mIBG for neuroblastoma (59%), and 131I-NaI for benign thyroid diseases (54%). The majority of therapies were prescribed based on fixed-activity protocols. The highest number of absorbed-dose based prescriptions were reported for 90Y microsphere treatments in the liver (64% and 96% of responses for resin and glass, respectively), 131I-NaI treatment of benign thyroid diseases (38% of responses), and for 131I-mIBG treatment of neuroblastoma (18% of responses). There is a wide variation in MRT practice across Europe and for different therapies, including the extent of medical-physicist involvement and the implementation of dosimetry-guided treatments.


  • The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy

    by C. Chiesa, K. Sjogreen Gleisner, G. Flux, J. Gear, S. Walrand, K. Bacher, U. Eberlein, E. P. Visser, N. Chouin, M. Ljungberg, et al.